Neladalkib Shows Durable Responses in Heavily Pretreated ALK . . . Topline data from the ALKOVE-1 phase 1 2 clinical trial (NCT05384626) demonstrate neladalkib’s (NVL-655; Nuvalent) promise for treatment of patients with advanced ALK-positive non-small cell lung cancer (NSCLC) previously treated with tyrosine kinase inhibitors (TKI) The data showed an objective response rate (ORR) of 31% (95% CI: 26, 37), with an estimated durability of response of 64% and
Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC) Data on the efficacy and safety of adjuvant
Nuvalent Announces Positive Topline Pivotal Data from ALKOVE . . . Neladalkib has received breakthrough therapy designation from the U S Food and Drug Administration (FDA) for the treatment of patients with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) who have been previously treated with 2 or more ALK tyrosine kinase inhibitors and orphan drug designation for ALK-positive NSCLC
ALK Alterations and Treatment Options for ALK+ NSCLC Panelists review the discovery of ALK gene fusions and how they have reshaped the treatment landscape for a distinct subset of lung cancer patients They describe how these rearrangements activate
Real-world treatment sequencing and effectiveness of second . . . With multiple targeted therapies approved for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), it is increasingly important to understand outcomes with various sequences of next-generation ALK tyrosine kinase inhibitors (TKIs) We describe contemporary sequencing patterns and treatment effectiveness of first-line (1L) and second-line (2L) treatments in